Back
THE PERSISTANCE OF RESIDUAL VEIN THROMBOSIS, AFTER AN EPISODE OF DEEP VEIN THROMBOSIS, AND THE RISK OF NEW OVERT CANCER AND CARDIOVASCULAR DISEASE
Abstract number: P-T-498
Siragusa1 S., Cigna1 V., Malato1 A., Fulfaro2 F., Lo Coco1 L., Anastasio1 R., Abbene1 I., Saccullo1 G., Casuccio3 A.
11Thrombosis Haemostasis and Haematology Unit 22Oncology 33Epidemiology and Biostatistics, University Hospital of Palermo, Palermo, Italy
How-to-cite Siragusa S, Cigna V, Malato A, Fulfaro F, Lo Coco L, Anastasio R, Abbene I, Saccullo G, Casuccio A. THE PERSISTANCE OF RESIDUAL VEIN THROMBOSIS, AFTER AN EPISODE OF DEEP VEIN THROMBOSIS, AND THE RISK OF NEW OVERT CANCER AND CARDIOVASCULAR DISEASE. J Thromb Haemost 2007; 5 Supplement 2: P-T-498
Abstract
Introduction: Residual Vein Thrombosis (RVT) is a risk factor for recurrent thrombosis. At the present, it is unknown whether RVT may also identify patients at increased risk for cancer and/or cardiovascular disease (CD). We prospectively evaluated the correlation between RVT and the risk of new overt cancer and/or CD in patients with a first episode of Deep Vein Thrombosis (DVT).
Methods: Consecutive patients with idiopathic or provoked DVT were evaluated after 3 months from the index DVT. At that time, presence/absence of RVT (Ultra-Sonography detected) was recorded. Patients with RVT continued OA for additional 9 months, while those without RVT stopped warfarin. Main exclusion criteria were: known cancer and/or CD. The incidence of recurrent venous thrombosis, overt cancer and new CD was recorded over a period of 3 years. Survival curves (Kaplan-Mayer) and related Breslow test have been used for statistics.
Results: 434 patients were included in the analysis (286 with and 148 without RVT). Index idiopathic DVT was present in 218 (76.2%) of patients with RVT and in 49 (33.1%) of those without RVT. Density incidence and mean time for cancer, CD and recurrent DVT (rDVT) in patients with and without RVT are listed in the table. Among these two groups, a statistically significant difference was found (p= 0.01, Log Rank Mantel-Cox) regarding new overt cancer and rDVT. Cumulative mortality was 14% and 6% in patients with and without RVT, respectively.
Table:
| | RVT patients (286) | No-RVT patients (148) |
|---|
| Cancer (density incidence*) | 41.9 | 9.1 |
| Mean time (monthsSD) | 14.3 (5.9) | 19.8 (4.6) |
| CD (density incidence*) | 34.6 | 16.1 |
| Mean time (monthsSD) | 18.1 (3.2) | 18.1 (4.3) |
| rDVT (density incidence*) | 69.4 | 6.9 |
| Mean time (monthsSD) | 17.7 (7.0) | 8.0 (1.0) |
| *cases × 1000 patients/year. |
Conclusions: Presence of RVT, after 3 months of OA, is a risk factor for recurrent VTE and indicates patients at risk for new overt cancer. This account for patients with idiopathic or provoked DVT and it is independent to the duration of OAs.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number
Session Details
| Date: |
01/08/2007
|
| Time: |
00:00-00:00
|
| Session name: |
XXIst ISTH Congress |
| Subject: |
|
| Location: |
Oxford, UK |
| Presentation type: |
|
| Back to top |
|
